Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria

2016107 citationsJournal Articlebronze Open Access

Authors

Nicholas J. White · Mahidol Oxford Tropical Medicine Research Unit

Tran Thanh Duong · Novartis (Singapore)

Chirapong Uthaisin · Maesot General Hospital

François Nosten · University of Oxford

Aung Pyae Phyo · Mahidol Oxford Tropical Medicine Research Unit

Borimas Hanboonkunupakarn · Mahidol Oxford Tropical Medicine Research Unit

Sasithon Pukrittayakamee

Abstract

KAF156 showed antimalarial activity without evident safety concerns in a small number of adults with uncomplicated P. vivax or P. falciparum malaria. (Funded by Novartis and others; ClinicalTrials.gov number, NCT01753323 .).

Topics & Keywords

Malaria Research and Control Computational Drug Discovery Methods Mosquito-borne diseases and control

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 12, pp. 1152-1160

DOI: 10.1056/nejmoa1602250

Field-Weighted Citation Impact: 13.92